Article
Circulating Tumor DNA in Gastric and Gastroesophageal Junction Cancer
25 Feb 2022
Abstract excerpt
Tumor cells shed DNA into the plasma. "Liquid biopsy" analysis of mutations or other genomic alterations in circulating cell-free DNA (cfDNA) may provide us with a tool to detect minimal residual cancer, comprehensively profile the genomic tumor landscape in search of druggable targets, and monitor cancers non-invasively over time for treatment failure or emerging treatment-resistant tumor subclones. While liquid...
Topics
Join the communities discussing this publication.
